ArticlePloS one2025

Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Agnies M van Eeghen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.